Granite Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.30 M
- Company Age 10 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 27.43%
- Profit Growth -7.62%
- Ebitda 9.84%
- Net Worth 6.12%
- Total Assets 18.10%
About Granite Pharmaceuticals
Granite Pharmaceuticals Private Limited (GPPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 December 2014 and has a history of Ten years and two months. Its registered office is in Patna, Bihar, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.30 M, as per Ministry of Corporate Affairs (MCA) records.
Rohit Shrivastav and Kumar Shailesh serve as directors at the Company.
Company Details
-
Location
Patna, Bihar, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24230BR2014PTC023350
-
Company No.
023350
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
16 Dec 2014
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Patna
Industry
Who are the key members and board of directors at Granite Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rohit Shrivastav
|
Managing Director | 16-Dec-2014 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Kumar Shailesh
|
Director | 16-Dec-2014 | Current |
Financial Performance of Granite Pharmaceuticals.
Granite Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 27.43% increase. The company also saw a slight decrease in profitability, with a 7.62% decrease in profit. The company's net worth moved up by a moderate rise of 6.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Granite Pharmaceuticals?
In 2017, Granite Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Zuventa Pharmaceuticals Private LimitedRohit Shrivastav is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Granite Pharmaceuticals?
Unlock and access historical data on people associated with Granite Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Granite Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Granite Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.